Welcome to our dedicated page for Cullinan Therapeutics news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Therapeutics stock.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a forward-thinking biopharmaceutical company dedicated to establishing new standards of care for patients through innovative cancer and autoimmune therapies. The company specializes in a modality-agnostic approach, targeting key drivers of disease and harnessing the immune system to eradicate diseased cells.
With a highly experienced team of oncology professionals and drug developers, Cullinan boasts a diversified portfolio of clinical-stage assets sourced from both internal and external collaborations. This includes therapies aimed at inhibiting disease drivers or activating the immune system to address various oncology and autoimmune indications.
Recent Achievements:
- CLN-617: A first-in-class cytokine therapy combining IL-2 and IL-12 for intratumoral injection, shown to activate a broad immune response.
- CLN-619: A first-in-class monoclonal antibody for relapsed/refractory multiple myeloma, aimed at restoring immune recognition of tumor cells.
- CLN-978: A novel CD19xCD3 bispecific T cell engager being developed for systemic lupus erythematosus.
- Zipalertinib: An EGFR inhibitor for non-small cell lung cancer, with promising efficacy and a manageable safety profile.
Financially, Cullinan is well-positioned, having announced a $280 million private placement to support ongoing research and development activities. This funding, combined with current assets, is expected to sustain the company's operations into 2028.
For more detailed insights and updates, visit Cullinan’s website or follow them on LinkedIn and Twitter.
Rhea-AI Summary
Cullinan Oncology, Inc. (CGEM) announces participation in investor conferences to discuss Gynecologic Cancers and financial updates. The Chief Medical Officer and Chief Financial Officer will be presenting at the TD Cowen and Leerink Partners conferences, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
-
Rhea-AI Summary
Cullinan Oncology, Inc. (Nasdaq: CGEM) announced that CEO Nadim Ahmed will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The presentation will be available via live webcast on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
-
Rhea-AI Summary
Cullinan Oncology, Inc. (Nasdaq: CGEM) announced the dosing of the first patient with CLN-617 in a Phase 1 clinical trial. CLN-617 is a first-in-class cytokine therapy designed for intratumoral injection, combining human IL-2, IL-12, a collagen binding domain, and a size-enhancing domain. The therapy aims to promote retention of the cytokines in the injected tumor and potentially provide enhanced safety and efficacy. In pre-clinical models, CLN-617 stimulated a broad systemic immune response, leading to the regression of non-injected distal tumors and the generation of a memory T cell response that enhanced long-term survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
Rhea-AI Summary
Cullinan Oncology, Inc. (Nasdaq: CGEM) reported on recent business highlights and financial results for Q3 2023. They expect to provide clinical data updates on three novel targeted oncology programs in 2024 and have a cash and investment position of $482 million as of September 30, 2023, expected to provide runway into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
-
Rhea-AI Summary
Cullinan Oncology, Inc. will present data across four immuno-oncology programs in five poster presentations at the Society for Immunotherapy of Cancer 2023 Annual Meeting. The data supports the proposed mechanism of action and demonstrates clinical activity in patients with tumors not typically responsive to checkpoint inhibitor therapy. The presentations will cover CLN-619, an anti-MICA/B antibody; CLN-418, a B7H4X4-1BB-bispecific immune activator; CLN-978, a CD19XCD3 bispecific T cell engager; and CLN-617, a fusion protein harnessing IL-2 and IL-12 cytokines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.53%
Tags
-
Rhea-AI Summary
Cullinan Oncology, a biopharmaceutical company, will participate in upcoming investor conferences including the TD Cowen 7th Annual Fall Oncology Innovation Summit, the Stifel 2023 Healthcare Conference, and the Evercore ISI HealthCONx Conference. Webcasts of these events will be available on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
Rhea-AI Summary
Cullinan Oncology to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
-
Rhea-AI Summary
Cullinan Oncology has announced the dosing of the first patient in a Phase 1 clinical trial for CLN-978, a targeted oncology therapy for relapsed/refractory B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the treatment. CLN-978 has a differentiated profile with high affinity to CD19-expressing cells and offers patient-friendly administration. This marks Cullinan Oncology's fifth program in the clinic.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
Rhea-AI Summary
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. announced the launch of the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and chemotherapy as a potential first-line treatment for adult patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) exon 20 insertion mutation. This trial aims to assess progression-free survival of zipalertinib plus chemotherapy versus chemotherapy in adult patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR exon 20 insertion mutations. Results from a Phase 1/2a clinical trial of zipalertinib in patients with NSCLC harboring EGFR exon 20 insertion mutations demonstrated its therapeutic potential and were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
FAQ
What is the current stock price of Cullinan Therapeutics (CGEM)?
The current stock price of Cullinan Therapeutics (CGEM) is $11.6 as of December 20, 2024.
What is the market cap of Cullinan Therapeutics (CGEM)?
The market cap of Cullinan Therapeutics (CGEM) is approximately 684.2M.
What does Cullinan Therapeutics, Inc. specialize in?
Cullinan Therapeutics, Inc. specializes in developing innovative cancer and autoimmune therapies, utilizing a modality-agnostic approach to target key drivers of disease and harness the immune system.
What is CLN-617?
CLN-617 is a first-in-class cytokine therapy combining IL-2 and IL-12 for intratumoral injection, designed to activate a broad immune response against cancer cells.
What is the purpose of the recent $280 million private placement?
The $280 million private placement is intended to support Cullinan’s ongoing research and development activities, expand its clinical programs, and fund general corporate purposes and working capital.
What is Zipalertinib?
Zipalertinib is an orally available EGFR inhibitor designed to target exon 20 insertion mutations in non-small cell lung cancer, demonstrating promising efficacy and a manageable safety profile.
What are the latest developments regarding CLN-619?
CLN-619 is a monoclonal antibody targeting relapsed/refractory multiple myeloma, with Phase 1 trials indicating its potential to restore immune recognition and attack tumor cells.
What types of diseases does Cullinan Therapeutics' portfolio address?
Cullinan’s portfolio addresses both oncology and autoimmune diseases through a range of modalities designed to inhibit disease drivers or activate the immune system.
What is the strategic focus of Cullinan Therapeutics?
Cullinan focuses on creating transformative therapeutics by identifying unique targets and selecting optimal modalities, leveraging deep expertise in oncology, immunology, and translational medicine.
What is CLN-978 and its target indication?
CLN-978 is a novel CD19xCD3 bispecific T cell engager aimed at treating systemic lupus erythematosus and potentially other autoimmune diseases.
How does Cullinan Therapeutics ensure the development of promising assets?
Cullinan applies rigorous go/no-go criteria at each development stage to fast-track only the most promising molecules from candidate selection to clinical and commercial stages.
Where can I find more information about Cullinan Therapeutics?
More information about Cullinan Therapeutics can be found on their website at www.cullinantherapeutics.com and by following them on LinkedIn and Twitter.
Cullinan Therapeutics, Inc.
Nasdaq:CGEM
CGEM Rankings
CGEM Stock Data
684.17M
52.75M
4.5%
118.78%
14.96%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
CAMBRIDGE